|Description||AZ0108 is an orally bioavailable, PARP1,2,6 inhibitor that causes a multi-polar spindle phenotype at double digit nM concentrations. AZ0108 has been utilized as in vitro tools and in vivo probes to investigate the biological consequences of inhibiting centrosome clustering through PARP enzymes.|
|Synonyms||(S)-4-((3-(3-(1,1-difluoroethyl)-6-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)phenyl)difluoromethyl)phthalazin-1(2H)-one; AZ0108; AZ-0108; AZ 0108.|
Parstatin is a 41-amino acid peptide, formed by proteolytic cleavage on activation of the protease activated receptor-1, with antiangiogenic properties. Parstat...
INO1001 is an isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitiza...
1,5-Isoquinolinediol is a PARP1 inhibitor (IC50 value 0.39 - 1.00 μM) and neuroprotective agent leading to an increase up to 8-fold in the absolute frequency of...
RWJ 56110 is a selective Thrombin R protease-activated receptor (PAR)-1 antagonist which exhibits no activity at PAR2, PAR3, or PAR4 subtypes. It blocks thrombi...
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...
NMS-P118 is a highly selective Poly(ADP-ribose) Polymerase 1 (PARP-1) inhibitor with excellent ADME, pharmacokinetic profiles and high efficacy in vivo originat...
DR 2313 has been found to be a PARP-1/PARP-2 inhibitor and could exhibit neuroprotective avtivities as well as reduce cortical infarct volume in focal ischemia.
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-...